Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma

Eur J Surg Oncol. 2004 Jun;30(5):544-50. doi: 10.1016/j.ejso.2004.03.007.

Abstract

Aim: To investigate whether results of [F-18]-fluorodeoxy-d-glucose (FDG) positron emission tomography (PET) of esophageal cancer (EC) before and after neoadjuvant radio-chemotherapy correlate with histopathology after esophageal resection.

Methods: Twenty consecutive patients with EC without distant metastases were examined twice with 18F-FDG-PET during primary staging and after neoadjuvant radio-chemotherapy. FDG standardised uptake values (SUV) were correlated with the histopathological findings (percentage of viable tumour cells, tumour regression grade 1-5).

Results: Regression analysis revealed a slight (not significant) positive correlation between SUV(pre) (R=0.41, p=0.08) and SUV(post) (R=0.37, p=0.11) and the percentage of viable tumour cells in the resectate. Although all patients showed a significant decrease in SUV after radio-chemotherapy (p < 0.01) the percentual decrease of the SUV after therapy (DeltaSUV%) did not significantly differ between the TRG-groups. In 12 of 20 patients (60%), therapy-induced esophagitis was detected in post-therapeutic PET images.

Conclusion: In EC, a higher pre-therapeutic SUV might be correlated with a higher fraction of vital tumour cells remaining after radio-chemotherapy. Applying the neoadjuvant therapy protocol and the study design used in this examination, there is no correlation between decrease in SUV and histopathology.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / classification
  • Adenocarcinoma / diagnosis*
  • Adenocarcinoma / therapy*
  • Adult
  • Aged
  • Chemotherapy, Adjuvant / adverse effects
  • Esophageal Neoplasms / classification
  • Esophageal Neoplasms / diagnosis*
  • Esophageal Neoplasms / therapy*
  • Esophagitis / chemically induced
  • Esophagitis / radiotherapy
  • Esophagus / diagnostic imaging
  • Esophagus / pathology
  • Female
  • Fluorodeoxyglucose F18 / therapeutic use*
  • Germany
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Radiopharmaceuticals / therapeutic use*
  • Radiotherapy, Adjuvant / adverse effects
  • Statistics as Topic
  • Tomography, Emission-Computed*
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18